Preprint / Version 1

SUCCESSFUL USE OF COVID-19 CONVALESCENT PLASMA IN A PATIENT WITH MULTIPLE MYELOMA CHEMOTHERAPY

##article.authors##

  • Carlos Flores-Angulo Hospital Regional Libertador Bernardo O´Higgins https://orcid.org/0000-0001-9148-8379
  • Ada Hernández Hospital Regional Libertador Bernardo O´Higgins
  • Carla Salvo Centro de Sangre de Valparaíso
  • Maria Alicia Cid Lagos Hospital Regional Libertador Bernardo O´Higgins
  • Karen Martínez-Jofré Hospital Regional Libertador Bernardo O´Higgins
  • Carmen Vergara Hospital Regional Libertador Bernardo O´´Higgins
  • Karin Martínez Centro de Sangre de Valparaíso
  • Dafne Donoso Rival Hospital Regional Libertador Bernardo O´Higgins
  • Felipe Vergara Fuentes Hospital Regional Libertador Bernardo O´Higgins
  • Guillermo Silva Hospital Regional Libertador Bernardo O´Higgins

DOI:

https://doi.org/10.1590/SciELOPreprints.1859

Keywords:

multiple myeloma, convalescent plasma, COVID-19, SARS-CoV-2

Abstract

Multiple myeloma (MM) is a clonal disease derived from plasma cells, whose biology and treatment can produce immunosuppression, which could explain the high mortality rate of patients with MM and COVID-19. The following describes the clinical course of a 63-year-old patient with arterial hypertension, type 2 diabetes mellitus, relapsed MM receiving chemotherapy and SARS-CoV-2 infection who presented a rapid deterioration of respiratory function, requiring orotracheal intubation and admission to the Intensive Care Unit of the HRLBO. Due to the progressive worsening of ventilatory parameters, and considering the different risk factors, it was decided to administer 200 cc of convalescent plasma, showing clinical improvement 24 hours after infusion; finally, the patient was extubated and transferred to the Intermediate Care Unit where she was subsequently discharged.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Posted

2021-03-01

Section

Health Sciences